Case Report

Embryonal Rhabdomyosarcoma Secondary to an Open Fracture of the Tibia: A Case Report and Review of Literature

Authors: Olav Gressner MD, Tilman Saurbruch MD

Abstract

Embryonal rhabdomyosarcoma (ERMS) is a highly malignant tumor in children and adolescents. It rarely occurs in adults. A 47-year-old patient presented with ERMS of the muscle flap transplant 20 years after an open type III-comminuted fracture of the lower leg. The affected leg was amputated. The patient refused adjuvant chemotherapy and one year after surgery remains disease-free and in good general condition.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gurney JG, Severson RK, Davis S, et al. Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995;75:2186–2195.
 
2. Maurer HM, Gehan EA, Bettangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904–1922.
 
3. Carli M, Colombatti R, Oberlin O, et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 2004;22:4787–4794.
 
4. Aaronson SA. Influences of growth factors and their signaling pathways in malignancy. Harvey Lect 1991;87:17–34.
 
5. Witwicki T, Daniluk A, Dulowski W, et al. [Two cases of sarcoma developing at the site of fracture and metallic osteosynthesis]. Wiad Lek 1976;29:339–343.
 
6. Bykovchenko GV. [Rhabdomyosarcoma of the knee developing 22 years after a gunshot wound]. Vopr Onkol 1967;13:118–119.
 
7. Cureton RJ, Griffiths JD. Rhabdomyosarcoma of the hand following severe trauma. Br J Surg 1957;44:509–513.
 
8. Rather LJ. The Genesis of Cancer: A Study in the History of Ideas. Baltimore, Johns Hopkins University Press, 1978, pp 262.
 
9. Virchow R. Die krankhaften Geschwulste, Berlin. 1863–1867.
 
10. Sporn MB, Roberts AB. Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest 1986;78:329–332.
 
11. George D. Targeting PDGF receptors in cancer: rationales and proof of concept clinical trials. Adv Exp Med Biol 2003;532:141–151.
 
12. Greenhalgh DG, Sprugel KH, Murray MJ, et al. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990;136:1235–1246.
 
13. O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol 1997;29:63–78.
 
14. Pierce GF, Mustoe TA, Altrock BW, et al. Role of platelet-derived growth factor in wound healing. J Cell Biochem 1991;45:319–326.
 
15. Riordan JF. Angiogenin. Methods Enzymol 2001;341:263–273.
 
16. Wang W, Kumar P, Wang W, et al. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res 1998;58:4426–4433.
 
17. Yamazaki K, Nagao T, Yamaguchi T, et al. Expression of basic fibroblast growth factor (FGF-2)-associated with tumour proliferation in human pancreatic carcinoma. Virchows Arch 1997;431:95–101.
 
18. Akhurst RJ, Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol 1999;187:82–90.
 
19. Kaklamani VG, Pasche B. Role of TGF-beta in cancer and the potential for therapy and prevention. Exp Rev Anticancer Ther 2004;4:649–661.